These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
163 related articles for article (PubMed ID: 31964688)
21. Isolation and characterization of mesoangioblasts from facioscapulohumeral muscular dystrophy muscle biopsies. Morosetti R; Mirabella M; Gliubizzi C; Broccolini A; Sancricca C; Pescatori M; Gidaro T; Tasca G; Frusciante R; Tonali PA; Cossu G; Ricci E Stem Cells; 2007 Dec; 25(12):3173-82. PubMed ID: 17761758 [TBL] [Abstract][Full Text] [Related]
22. [Skeletal muscle MRI of lower limbs in patients with facioscapulohumeral dystrophy]. Ma MM; Song J; Zhang JW; Gao L; Pang M; Li G; Fu J Zhonghua Yi Xue Za Zhi; 2019 Mar; 99(9):675-679. PubMed ID: 30831616 [No Abstract] [Full Text] [Related]
23. Assessement of quadriceps strength, endurance and fatigue in FSHD and CMT: benefits and limits of femoral nerve magnetic stimulation. Bachasson D; Temesi J; Bankole C; Lagrange E; Boutte C; Millet GY; Verges S; Levy P; Feasson L; Wuyam B Clin Neurophysiol; 2014 Feb; 125(2):396-405. PubMed ID: 24001968 [TBL] [Abstract][Full Text] [Related]
24. Trunk muscle involvement is most critical for the loss of balance control in patients with facioscapulohumeral muscular dystrophy. Rijken NH; van Engelen BG; de Rooy JW; Geurts AC; Weerdesteyn V Clin Biomech (Bristol, Avon); 2014 Sep; 29(8):855-60. PubMed ID: 25156185 [TBL] [Abstract][Full Text] [Related]
25. Evaluation of muscle oxygenation by near infrared spectroscopy in patients with facioscapulohumeral muscular dystrophy. Olivier N; Boissière J; Allart E; Mucci P; Thevenon A; Daussin F; Tiffreau V Neuromuscul Disord; 2016 Jan; 26(1):47-55. PubMed ID: 26608622 [TBL] [Abstract][Full Text] [Related]
26. Facioscapulohumeral muscular dystrophy (FSHD) region gene 1 (FRG1) is a dynamic nuclear and sarcomeric protein. Hanel ML; Sun CY; Jones TI; Long SW; Zanotti S; Milner D; Jones PL Differentiation; 2011 Feb; 81(2):107-18. PubMed ID: 20970242 [TBL] [Abstract][Full Text] [Related]
27. Muscle pathology grade for facioscapulohumeral muscular dystrophy biopsies. Statland JM; Shah B; Henderson D; Van Der Maarel S; Tapscott SJ; Tawil R Muscle Nerve; 2015 Oct; 52(4):521-6. PubMed ID: 25704033 [TBL] [Abstract][Full Text] [Related]
29. Muscle strength, quantity and quality and muscle fat quantity and their association with oxidative stress in patients with facioscapulohumeral muscular dystrophy: Effect of antioxidant supplementation. Wilson VD; Bommart S; Passerieux E; Thomas C; Pincemail J; Picot MC; Mercier J; Portet F; Arbogast S; Laoudj-Chenivesse D Free Radic Biol Med; 2024 Jul; 219():112-126. PubMed ID: 38574978 [TBL] [Abstract][Full Text] [Related]
30. Sensitivity of motor unit potential analysis in facioscapulohumeral muscular dystrophy. Podnar S; Zidar J Muscle Nerve; 2006 Oct; 34(4):451-6. PubMed ID: 16830333 [TBL] [Abstract][Full Text] [Related]
31. Upper extremity kinematics and muscle activation patterns in subjects with facioscapulohumeral dystrophy. Bergsma A; Murgia A; Cup EH; Verstegen PP; Meijer K; de Groot IJ Arch Phys Med Rehabil; 2014 Sep; 95(9):1731-41. PubMed ID: 24780289 [TBL] [Abstract][Full Text] [Related]
32. Generation of isogenic D4Z4 contracted and noncontracted immortal muscle cell clones from a mosaic patient: a cellular model for FSHD. Krom YD; Dumonceaux J; Mamchaoui K; den Hamer B; Mariot V; Negroni E; Geng LN; Martin N; Tawil R; Tapscott SJ; van Engelen BG; Mouly V; Butler-Browne GS; van der Maarel SM Am J Pathol; 2012 Oct; 181(4):1387-401. PubMed ID: 22871573 [TBL] [Abstract][Full Text] [Related]
33. Safety and efficacy of a 6-month home-based exercise program in patients with facioscapulohumeral muscular dystrophy: A randomized controlled trial. Bankolé LC; Millet GY; Temesi J; Bachasson D; Ravelojaona M; Wuyam B; Verges S; Ponsot E; Antoine JC; Kadi F; Féasson L Medicine (Baltimore); 2016 Aug; 95(31):e4497. PubMed ID: 27495097 [TBL] [Abstract][Full Text] [Related]
34. Beevor's sign in facioscapulohumeral muscular dystrophy: an old sign with new implications. Eger K; Jordan B; Habermann S; Zierz S J Neurol; 2010 Mar; 257(3):436-8. PubMed ID: 19838767 [TBL] [Abstract][Full Text] [Related]
35. Inflammatory response in facioscapulohumeral muscular dystrophy (FSHD): immunocytochemical and genetic analyses. Arahata K; Ishihara T; Fukunaga H; Orimo S; Lee JH; Goto K; Nonaka I Muscle Nerve Suppl; 1995; (2):S56-66. PubMed ID: 23573588 [TBL] [Abstract][Full Text] [Related]
36. Facioscapulohumeral dystrophy in children: design of a prospective, observational study on natural history, predictors and clinical impact (iFocus FSHD). Goselink RJ; Schreuder TH; Mul K; Voermans NC; Pelsma M; de Groot IJ; van Alfen N; Franck B; Theelen T; Lemmers RJ; Mah JK; van der Maarel SM; van Engelen BG; Erasmus CE BMC Neurol; 2016 Aug; 16():138. PubMed ID: 27530735 [TBL] [Abstract][Full Text] [Related]
37. miRNA expression in control and FSHD fetal human muscle biopsies. Portilho DM; Alves MR; Kratassiouk G; Roche S; Magdinier F; de Santana EC; Polesskaya A; Harel-Bellan A; Mouly V; Savino W; Butler-Browne G; Dumonceaux J PLoS One; 2015; 10(2):e0116853. PubMed ID: 25692472 [TBL] [Abstract][Full Text] [Related]
38. Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration. Janssen BH; Voet NB; Nabuurs CI; Kan HE; de Rooy JW; Geurts AC; Padberg GW; van Engelen BG; Heerschap A PLoS One; 2014; 9(1):e85416. PubMed ID: 24454861 [TBL] [Abstract][Full Text] [Related]